Another clinical trial in multiple myeloma demonstrated that the combination of ulocuplumab with standard chemotherapies resulted in a progression-free survival rate greater than results in the standard therapy alone from previous trials, indicating that anti-CXCR4 treatment may enhance the efficacy and longevity of the standard treatment response in hematological cancers [203]. This evidence concerns the gene CXCR4 and plasma cell myeloma.